See more : TreeHouse Foods, Inc. (THS) Income Statement Analysis – Financial Results
Complete financial analysis of Heron Therapeutics, Inc. (HRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Heron Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lakeshore Acquisition II Corp. (LBBB) Income Statement Analysis – Financial Results
- Metromile, Inc. (MILEW) Income Statement Analysis – Financial Results
- Tips Industries Limited (TIPSINDLTD.BO) Income Statement Analysis – Financial Results
- BLOK Technologies Inc. (BLPFF) Income Statement Analysis – Financial Results
- baby calendar Inc. (7363.T) Income Statement Analysis – Financial Results
Heron Therapeutics, Inc. (HRTX)
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.04M | 107.67M | 86.35M | 88.64M | 145.97M | 77.47M | 30.77M | 1.28M | 0.00 | 0.00 | 0.00 | 0.00 | 646.00K | 1.30M | 1.26M | 369.00K | 412.00K | 0.00 | 5.39M | 5.40M | 4.85M | 5.82M | 4.39M | 3.37M | 20.40M | 20.00M | 18.30M | 18.70M | 16.10M | 15.90M | 19.90M | 7.30M | 2.80M | 2.40M | 2.80M | 2.50M | 1.70M |
| Cost of Revenue | 65.11M | 54.87M | 46.02M | 36.19M | 61.62M | 27.51M | 4.59M | 35.00K | 734.00K | 54.83M | 30.92M | 14.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 445.00K | 440.27K | 613.20K | 6.40M | 5.70M | 6.00M | 9.40M | 9.80M | 9.00M | 11.60M | 3.80M | 1.10M | 1.20M | 700.00K | 600.00K | 400.00K |
| Gross Profit | 61.94M | 52.80M | 40.33M | 52.45M | 84.35M | 49.96M | 26.18M | 1.24M | -734.00K | -54.83M | -30.92M | -14.08M | 646.00K | 1.30M | 1.26M | 369.00K | 412.00K | 0.00 | 5.39M | 5.40M | 4.85M | 5.37M | 3.95M | 2.75M | 14.00M | 14.30M | 12.30M | 9.30M | 6.30M | 6.90M | 8.30M | 3.50M | 1.70M | 1.20M | 2.10M | 1.90M | 1.30M |
| Gross Profit Ratio | 48.75% | 49.04% | 46.70% | 59.17% | 57.79% | 64.49% | 85.09% | 97.26% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 100.00% | 100.00% | 92.35% | 89.96% | 81.78% | 68.63% | 71.50% | 67.21% | 49.73% | 39.13% | 43.40% | 41.71% | 47.95% | 60.71% | 50.00% | 75.00% | 76.00% | 76.47% |
| Research & Development | 55.90M | 107.51M | 130.82M | 174.53M | 167.38M | 140.03M | 138.58M | 103.13M | 61.18M | 54.83M | 32.78M | 15.05M | 8.21M | 7.26M | 7.80M | 19.51M | 19.36M | 15.24M | 10.30M | 11.50M | 8.66M | 6.70M | 7.35M | 3.71M | 4.30M | 4.40M | 3.70M | 3.50M | 4.10M | 6.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 49.01M | 37.44M | 40.15M | 42.23M | 37.90M | 29.26M | 25.55M | 21.37M | 35.74M | 19.73M | 21.68M | 8.79M | 3.50M | 3.97M | 3.71M | 4.31M | 4.68M | 3.63M | 3.57M | 3.23M | 2.80M | 3.50M | 3.30M | 3.46M | 6.50M | 6.00M | 7.40M | 11.40M | 9.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 67.64M | 82.51M | 87.18M | 63.85M | 89.76M | 64.60M | 56.60M | 47.67M | 17.35M | 8.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 116.66M | 119.95M | 127.33M | 106.08M | 127.66M | 93.87M | 82.16M | 69.03M | 35.74M | 19.73M | 21.68M | 8.79M | 3.50M | 3.97M | 3.71M | 4.31M | 4.68M | 3.63M | 3.57M | 3.23M | 2.80M | 3.50M | 3.30M | 3.46M | 6.50M | 6.00M | 7.40M | 11.40M | 9.60M | 8.50M | 17.50M | 8.80M | 4.90M | 5.10M | 6.70M | 6.90M | 4.50M |
| Other Expenses | 0.00 | -7.37M | -2.86M | 885.00K | 5.95M | 5.10M | -38.00K | -2.23M | -666.00K | -1.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -116.76K | 500.00K | 1.40M | 1.20M | 1.40M | 1.20M | 1.10M | 1.20M | 1.10M | 800.00K | 800.00K | 700.00K | 900.00K | 900.00K |
| Operating Expenses | 172.55M | 227.46M | 258.15M | 280.61M | 295.04M | 233.90M | 220.74M | 172.16M | 96.93M | 74.56M | 54.46M | 23.83M | 11.71M | 11.24M | 11.50M | 23.81M | 24.05M | 18.86M | 13.86M | 14.72M | 11.46M | 10.19M | 10.65M | 7.06M | 11.30M | 11.80M | 12.30M | 16.30M | 14.90M | 15.90M | 18.70M | 9.90M | 5.70M | 5.90M | 7.40M | 7.80M | 5.40M |
| Cost & Expenses | 237.66M | 282.33M | 304.17M | 316.80M | 356.66M | 261.41M | 225.33M | 172.19M | 96.93M | 74.56M | 54.46M | 23.83M | 11.71M | 11.24M | 11.50M | 23.81M | 24.05M | 18.86M | 13.86M | 14.72M | 11.46M | 10.64M | 11.09M | 7.67M | 17.70M | 17.50M | 18.30M | 25.70M | 24.70M | 24.90M | 30.30M | 13.70M | 6.80M | 7.10M | 8.10M | 8.40M | 5.80M |
| Interest Income | 3.36M | 1.64M | 433.00K | 3.63M | 7.26M | 5.97M | 1.05M | 445.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 587.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.87M | 2.47M | 2.41M | 1.90M | 1.47M | 2.67M | 3.94M | 2.66M | 958.00K | 887.00K | 826.00K | 599.00K | 373.00K | 2.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.90M | 2.89M | 3.02M | 2.85M | 2.04M | 1.51M | 1.53M | 1.10M | 734.00K | 578.00K | 333.00K | 197.00K | 179.00K | 227.00K | 356.00K | 412.00K | 289.00K | -244.00K | 446.00K | 314.00K | 460.00K | 482.00K | 406.06K | -116.76K | 500.00K | 1.40M | 1.20M | 1.40M | 1.20M | 1.10M | 1.20M | 1.10M | 800.00K | 800.00K | 700.00K | 900.00K | 900.00K |
| EBITDA | -103.79M | -176.66M | -215.25M | -222.53M | -201.23M | -174.66M | -192.02M | -169.38M | -96.19M | -73.98M | -54.46M | -23.83M | -10.88M | -6.97M | -9.86M | -22.51M | -19.44M | 5.91M | -8.03M | -9.02M | -5.96M | -4.58M | -6.77M | -4.03M | -1.50M | -2.00M | -800.00K | -7.10M | -7.40M | -7.90M | -9.20M | -5.30M | -3.20M | -3.90M | -4.60M | -5.00M | -3.20M |
| EBITDA Ratio | -81.70% | -162.21% | -252.27% | -257.41% | -142.94% | -237.42% | -624.10% | -13,363.17% | 0.00% | 0.00% | 0.00% | 0.00% | -1,684.67% | -956.73% | -783.58% | -6,223.85% | -6,274.51% | 0.00% | -148.95% | -166.99% | -130.05% | -75.84% | -145.49% | -132.20% | 15.69% | 18.50% | 4.92% | -24.06% | -44.72% | -47.80% | -50.75% | -83.56% | -128.57% | -204.17% | -196.43% | -244.00% | -217.65% |
| Operating Income | -110.62M | -174.66M | -217.83M | -228.16M | -210.69M | -183.94M | -194.56M | -170.92M | -96.93M | -74.56M | -54.46M | -23.83M | -11.06M | -9.93M | -10.24M | -23.45M | -23.63M | -18.86M | -8.47M | -9.32M | -6.61M | -4.82M | -6.70M | -4.31M | 2.70M | 2.50M | -300.00K | -7.00M | -8.60M | -9.00M | -10.40M | -6.40M | -4.00M | -4.70M | -5.30M | -5.90M | -4.10M |
| Operating Income Ratio | -87.07% | -162.21% | -252.27% | -257.41% | -144.34% | -237.42% | -632.36% | -13,363.17% | 0.00% | 0.00% | 0.00% | 0.00% | -1,712.38% | -763.57% | -812.21% | -6,353.66% | -5,736.17% | 0.00% | -157.17% | -172.39% | -136.39% | -82.96% | -152.79% | -127.96% | 13.24% | 12.50% | -1.64% | -37.43% | -53.42% | -56.60% | -52.26% | -87.67% | -142.86% | -195.83% | -189.29% | -236.00% | -241.18% |
| Total Other Income/Expenses | 56.00K | -7.37M | -2.86M | 885.00K | 5.95M | 5.10M | -2.93M | -2.23M | -666.00K | -1.81M | -826.00K | -599.00K | -373.00K | 2.74M | 24.00K | 520.00K | 3.83M | 24.38M | 290.00K | 224.00K | 153.00K | 297.00K | 712.64K | 26.39K | 0.00 | 200.00K | 300.00K | 400.00K | -200.00K | -300.00K | 900.00K | 600.00K | 0.00 | 1.00M | 900.00K | 1.10M | 500.00K |
| Income Before Tax | -110.56M | -182.02M | -220.68M | -227.28M | -204.75M | -178.84M | -197.48M | -173.14M | -97.59M | -76.37M | -55.28M | -24.43M | -11.44M | -7.20M | -10.15M | -23.13M | -19.80M | 5.52M | -8.47M | -9.29M | -6.46M | -4.76M | -6.62M | -4.28M | 0.00 | 2.70M | 0.00 | -8.10M | -8.80M | -9.30M | -9.50M | -5.80M | -4.00M | -3.70M | -4.40M | -4.80M | -3.60M |
| Income Before Tax Ratio | -87.02% | -169.05% | -255.58% | -256.41% | -140.27% | -230.84% | -641.87% | -13,537.37% | 0.00% | 0.00% | 0.00% | 0.00% | -1,770.12% | -553.11% | -804.92% | -6,266.94% | -4,805.83% | 0.00% | -157.11% | -171.98% | -133.23% | -81.79% | -150.83% | -127.18% | 0.00% | 13.50% | 0.00% | -43.32% | -54.66% | -58.49% | -47.74% | -79.45% | -142.86% | -154.17% | -157.14% | -192.00% | -211.76% |
| Income Tax Expense | 0.00 | -47.51M | -3.02M | -2.85M | 1.87M | 7.77M | 3.90M | -1.10M | -734.00K | -578.00K | -333.00K | -1.28M | 379.00K | -2.59M | -122.00K | -320.00K | 41.00K | 119.00K | -263.00K | -95.00K | -2.25M | -1.05M | -4.19M | -12.86M | 300.00K | 600.00K | 700.00K | 2.40M | 800.00K | 800.00K | -500.00K | -200.00K | 300.00K | -800.00K | -800.00K | -900.00K | -300.00K |
| Net Income | -110.56M | -134.52M | -217.66M | -224.43M | -204.75M | -178.84M | -197.48M | -173.14M | -97.59M | -76.37M | -55.28M | -23.35M | -11.81M | -7.35M | -10.03M | -23.13M | -20.16M | 5.27M | -8.21M | -9.22M | -4.36M | -3.78M | -2.51M | 8.55M | 2.40M | 1.90M | -700.00K | -9.40M | -9.40M | -9.80M | -9.90M | -5.60M | -4.30M | -3.90M | -4.50M | -5.00M | -3.80M |
| Net Income Ratio | -87.02% | -124.93% | -252.08% | -253.20% | -140.27% | -230.84% | -641.87% | -13,537.37% | 0.00% | 0.00% | 0.00% | 0.00% | -1,828.79% | -564.64% | -795.24% | -6,266.94% | -4,893.93% | 0.00% | -152.29% | -170.63% | -90.00% | -64.97% | -57.29% | 254.09% | 11.76% | 9.50% | -3.83% | -50.27% | -58.39% | -61.64% | -49.75% | -76.71% | -153.57% | -162.50% | -160.71% | -200.00% | -223.53% |
| EPS | -0.80 | -1.24 | -2.21 | -2.47 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 | -6.15 | -15.01 | -20.83 | 66.70 | -26.15 | -32.20 | -16.98 | -14.81 | -9.92 | 33.60 | 9.60 | 10.40 | -2.88 | -40.96 | -45.69 | -48.87 | -58.03 | -34.50 | -34.40 | -32.14 | -37.86 | -43.99 | -35.08 |
| EPS Diluted | -0.80 | -1.24 | -2.21 | -2.47 | -2.50 | -2.44 | -3.65 | -4.57 | -2.95 | -2.87 | -3.42 | -1.91 | -1.96 | -3.70 | -6.15 | -15.01 | -20.83 | 66.25 | -26.15 | -32.20 | -16.98 | -14.81 | -9.92 | 33.60 | 9.60 | 9.60 | -2.88 | -40.96 | -45.69 | -48.87 | -58.03 | -34.50 | -34.40 | -32.14 | -37.86 | -43.99 | -35.08 |
| Weighted Avg Shares Out | 138.14M | 108.88M | 98.47M | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | 1.98M | 1.63M | 1.54M | 967.90K | 78.95K | 313.98K | 286.36K | 256.91K | 255.11K | 253.45K | 252.24K | 250.99K | 248.18K | 243.31K | 229.50K | 205.74K | 200.54K | 170.59K | 162.33K | 124.99K | 121.34K | 118.85K | 113.65K | 108.33K |
| Weighted Avg Shares Out (Dil) | 138.14M | 108.88M | 98.47M | 90.77M | 81.78M | 73.19M | 54.04M | 37.93M | 33.08M | 26.57M | 16.16M | 12.22M | 6.01M | 1.98M | 1.63M | 1.54M | 967.90K | 79.49K | 313.98K | 286.36K | 256.91K | 255.11K | 253.45K | 252.43K | 253.15K | 254.76K | 243.31K | 229.50K | 205.74K | 200.54K | 170.59K | 162.33K | 124.99K | 121.34K | 118.85K | 113.65K | 108.33K |
7 Stocks Under $10 That Can Double in One Year
As the market continues to struggle, it isn't unreasonable to find stocks under $10 to double your money in a year. With the Federal Reserve signalling a shift to slower rate hikes, the U.S. markets have a reason to cheer.
7 Penny Stocks to Buy for 10-Bagger Returns
Some good news is finally starting to creep into the markets with inflation easing in October. However, GDP growth remains a concern.
Heron Therapeutics, Inc. (HRTX) Q3 2022 Earnings Call Transcript
Heron Therapeutics, Inc. (NASDAQ:HRTX ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - CEO and Chairman John Poyhonen - President and Chief Commercial Officer Conference Call...
Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Hurry! 7 Pitiful Stocks to Sell Before 2022 Ends
When it comes to certain stocks to sell, being overly optimistic can become a liability. No, this is not a popular topic by any means, usually arousing anger among the investing faithful.
4 No-Brainer Penny Stocks to Buy if You Have Money to Invest
Penny stocks have always fascinated investors. That's because higher-risk, lower-priced penny stocks to buy can be portfolio game-changers.
7 Unknown Biotech Stocks That Could Rocket in 2023
Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
Heron Therapeutics Is Not Out Of The Woods Yet
Heron addressed a key problem recently - its cash balance and cash burn. The cash raised and cost reductions have significantly extended the cash runway.
3 Stocks Expecting Good News From the FDA
Here are the upcoming catalysts for Mirati Therapeutics, Novavax, and Heron Therapeutics.
All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Buy
Heron Therapeutics (HRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Source: https://incomestatements.info
Category: Stock Reports